USP17L18: A Drug Target / Disease Biomarker (G100287364)
USP17L18: A Drug Target / Disease Biomarker
USP17L18 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the USP family of proteins, which are involved in the regulation of cell survival and growth. USP17L18 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
One of the key functions of USP17L18 is its role in cell signaling. It is a negative regulator of the TGF-β pathway, which is a well-known signaling pathway that is involved in the development and maintenance of tissues and organs. TGF-β is a transcription factor that plays a critical role in the regulation of cell growth, differentiation, and survival. It is a potent regulator of cell proliferation and has been implicated in the development of many diseases, including cancer.
USP17L18 is known to interact with several other proteins that are involved in the TGF-β pathway. One of the most well-studied of these interactions is its interaction with the protein SMAD4. SMAD4 is a transcription factor that is involved in the regulation of gene expression and is a direct target of TGF-β. USP17L18 and SMAD4 have been shown to work together in regulating cell survival and growth.
Another protein that is known to interact with USP17L18 is the protein p53. P53 is a transcription factor that is involved in the regulation of gene expression and is a critical factor in the regulation of cell growth and apoptosis. USP17L18 and p53 have been shown to work together in regulating cell survival and growth.
In addition to its role in cell signaling, USP17L18 is also known to play a role in the regulation of cellular processes that are important for tissue repair and regeneration. It is a regulator of the Wnt pathway, which is a critical pathway for the development and maintenance of tissues and organs. The Wnt pathway is involved in the regulation of cell proliferation, differentiation, and survival, and is implicated in the development of many diseases, including cancer.
USP17L18 is also known to play a role in the regulation of theNotch pathway, which is a critical pathway for the development and maintenance of neural tissues. The Notch pathway is involved in the regulation of cell survival and growth, and is implicated in the development of many neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
As a potential drug target or biomarker, USP17L18 is of interest because it is involved in the regulation of several important processes that are involved in the development and maintenance of tissues and organs. It is also known to interact with several other proteins that are involved in the TGF-β pathway and the regulation of cell growth and apoptosis. These interactions make USP17L18 a potential target for small molecules that can be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
In conclusion, USP17L18 is a protein that is expressed in various tissues of the body and is involved in the regulation of cell signaling, cellular processes important for tissue repair and regeneration, and the regulation of the Notch and TGF-β pathways. It is a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of USP17L18 in these processes and to develop effective treatments for these diseases.
Protein Name: Ubiquitin Specific Peptidase 17 Like Family Member 18
Functions: Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes that may include cell proliferation, progression through the cell cycle, apoptosis, cell migration, and the cellular response to viral infection
The "USP17L18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP17L18 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5
